Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease transmitted by X-linked inheritance with an incidence of approximately 1 in 3,500 live male births. DMD affects the muscles of respiration and is associated with dilated cardiomyopathy, which often leads to death from cardiopulmonary causes. Patients with DMD are especially vulnerable to the adverse physiologic effects of general anesthesia and procedural sedation, prompting the need for expert recommendations on this topic. This consensus statement is the product of a panel convened under the auspices of the American College of Chest Physicians’ (ACCP) Pediatric Chest Medicine and Home Care NetWorks. The panel consisted of specialists in the areas of anesthesiology, critical care medicine, neurology, orthopedic surgery, pediatric and adult pulmonology, and respiratory therapy. The most current and relevant medical literature was identified and reviewed, obtained by querying PubMed, a service of the National Library of Medicine and the National Institutes of Health (www.pubmed.gov), which includes the MEDLINE database. Consensus of recommendations was achieved through a majority vote of the panel members, and there were no disagreements on any of the recommendations. The purposes of this statement are to aid clinicians involved in the care of patients with DMD undergoing procedures requiring sedation or general anesthesia, to be a resource for other stakeholders in this field, including patients and their families, for use as an up-to-date summary of medical literature on this topic, and to identify areas in need of future research. The statement is divided into sections on the assessment and management of patients before, during, and after procedural sedation or general anesthesia.